{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:18:48Z","timestamp":1791256728439,"version":"4.1.0"},"reference-count":20,"publisher":"American Association for Cancer Research (AACR)","issue":"24","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cells carrying mutated BRCA1 or BRCA2 genes are defective in DNA repair by homologous recombination and, as a consequence, are highly sensitive to inhibitors of poly (ADP-ribose) polymerase (PARP). This provides the basis for a novel \u201csynthetic lethal\u201d approach to cancer therapy. We have recently shown that this sensitivity can be reversed, and resistance to PARP inhibition can be acquired by deletion of a mutation in BRCA2. Furthermore, a similar mechanism seems to be associated with carboplatin resistance in some BRCA2 mutation carriers with ovarian cancer. [Cancer Res 2008;68(24):10021\u20133]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-2287","type":"journal-article","created":{"date-parts":[[2008,12,15]],"date-time":"2008-12-15T08:33:36Z","timestamp":1229330016000},"page":"10021-10023","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Drug Resistance Caused by Reversion Mutation"],"prefix":"10.1158","volume":"68","author":[{"given":"Alan","family":"Ashworth","sequence":"first","affiliation":[{"name":"The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,12,15]]},"reference":[{"key":"2022061700274929000_B1","doi-asserted-by":"crossref","unstructured":"Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med\u20082003; 348: 2339\u201347.","DOI":"10.1056\/NEJMra012284"},{"key":"2022061700274929000_B2","doi-asserted-by":"crossref","unstructured":"Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene\u20082006; 25: 5864\u201374.","DOI":"10.1038\/sj.onc.1209874"},{"key":"2022061700274929000_B3","doi-asserted-by":"crossref","unstructured":"Tutt AN, Lord CJ, McCabe N, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harbor Symp Quant Biol\u20082005; 70: 139\u201348.","DOI":"10.1101\/sqb.2005.70.012"},{"key":"2022061700274929000_B4","doi-asserted-by":"crossref","unstructured":"Dobzhansky T. Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila Pseudoobscura. Genetics\u20081946; 31: 269\u201390.","DOI":"10.1093\/genetics\/31.3.269"},{"key":"2022061700274929000_B5","doi-asserted-by":"crossref","unstructured":"Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer\u20082005; 5: 689\u201398.","DOI":"10.1038\/nrc1691"},{"key":"2022061700274929000_B6","doi-asserted-by":"crossref","unstructured":"Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature\u20082005; 434: 917\u201321.","DOI":"10.1038\/nature03445"},{"key":"2022061700274929000_B7","doi-asserted-by":"crossref","unstructured":"Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature\u20082005; 434: 913\u20137.","DOI":"10.1038\/nature03443"},{"key":"2022061700274929000_B8","doi-asserted-by":"crossref","unstructured":"McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-Ribose) polymerase inhibition. Cancer Res\u20082006; 66: 8109\u201315.","DOI":"10.1158\/0008-5472.CAN-06-0140"},{"key":"2022061700274929000_B9","doi-asserted-by":"crossref","unstructured":"Yap TA, Boss DS, Fong PC, et al. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1\/2 mutation carriers. J Clin Oncol\u20082007; 25: 2007\u20133529.","DOI":"10.1200\/jco.2007.25.18_suppl.3529"},{"key":"2022061700274929000_B10","doi-asserted-by":"crossref","unstructured":"Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res\u20082007; 13: 1383\u20138.","DOI":"10.1158\/1078-0432.CCR-06-2260"},{"key":"2022061700274929000_B11","doi-asserted-by":"crossref","unstructured":"Edwards S, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature\u20082008; 451: 1111\u20135.","DOI":"10.1038\/nature06548"},{"key":"2022061700274929000_B12","doi-asserted-by":"crossref","unstructured":"McCabe N, Lord CJ, Tutt AN, et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther\u20082005; 4: 934\u20136.","DOI":"10.4161\/cbt.4.9.2141"},{"key":"2022061700274929000_B13","doi-asserted-by":"crossref","unstructured":"Lord CJ, Ashworth A. RAD51, BRCA2 and DNA repair: a partial resolution. Nat Struct Mol Biol\u20082007; 14: 461\u20132.","DOI":"10.1038\/nsmb0607-461"},{"key":"2022061700274929000_B14","doi-asserted-by":"crossref","unstructured":"Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer\u20082003; 97: 2187\u201395.","DOI":"10.1002\/cncr.11310"},{"key":"2022061700274929000_B15","doi-asserted-by":"crossref","unstructured":"Kelland L. The resurgence of platinum based cancer chemotherapy. Nat Rev Cancer\u20082007; 7: 573\u201384.","DOI":"10.1038\/nrc2167"},{"key":"2022061700274929000_B16","doi-asserted-by":"crossref","unstructured":"Borst P, Rottenberg S, Jonkers J. How do real tumours become resistant to cisplatin? Cell Cycle\u20082008; 7: 1353\u20136.","DOI":"10.4161\/cc.7.10.5930"},{"key":"2022061700274929000_B17","doi-asserted-by":"crossref","unstructured":"Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature\u20082008; 451: 1066\u20137.","DOI":"10.1038\/nature06633"},{"key":"2022061700274929000_B18","doi-asserted-by":"crossref","unstructured":"Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest\u20082007; 117: 2067\u201374.","DOI":"10.1172\/JCI31988"},{"key":"2022061700274929000_B19","doi-asserted-by":"crossref","unstructured":"Weinstock DM, Elliott B, Jasin M. A model of oncogenic rearrangements: differences between chromosomal translocation mechanisms and simple double-strand break repair. Blood\u20082006; 107: 777\u201380.","DOI":"10.1182\/blood-2005-06-2437"},{"key":"2022061700274929000_B20","doi-asserted-by":"crossref","unstructured":"Tutt A, Bertwistle D, Valentine J, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. Embo J\u20082001; 20: 4704\u201316.","DOI":"10.1093\/emboj\/20.17.4704"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/24\/10021\/2598823\/10021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/24\/10021\/2598823\/10021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T04:58:00Z","timestamp":1655441880000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/24\/10021\/541798\/Drug-Resistance-Caused-by-Reversion-Mutation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,15]]},"references-count":20,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2008,12,15]]},"published-print":{"date-parts":[[2008,12,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-2287","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,15]]}}}